Syntara (ASX:SNT)
ASX announcement history & article coverage
Transparent by design.
Announcments by Syntara (ASX:SNT) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
SNT-4728 Webinar Presentation
Encouraging SNT-4728 Phase 2 iRBD results
Trading Halt
Notification regarding unquoted securities - SNT
Application for quotation of securities - SNT
Proposed issue of securities to the CEO
SNT-9465 scarring trial exceeds 50% enrolment
Change in substantial holding
Section 708A(5)(e) notice
Application for quotation of securities - SNT
Results of Meeting
Application for quotation of securities - SNT
Results of Share Purchase Plan
Syntara completes $0.84M Share Purchase Plan, total raise $8.84M to fund clinical trials and development
SNT-4728 webinar presentation
SNT-4728 pre-readout informational webinar
Notice of General Meeting/Proxy Form
Update - Proposed issue of securities - SNT
Share Purchase Plan Offer Booklet
Syntara launches A$2 million Share Purchase Plan at A$0.027 per share following A$8 million placement
Change in substantial holding
Change in substantial holding
Section 708A(5)(e) notice
Application for quotation of securities - SNT
Investor Update Webinar
Quarterly Activities/Appendix 4C Cash Flow Report
Syntara advances clinical trials, secures $11.5m non-dilutive funding, raises $10m capital, and reports $16.9m cash
Investor update webinar
Proposed issue of securities - SNT
Proposed issue of securities - SNT
Equity Raising Presentation
Syntara launches A$8m equity raise to fund Phase 2b myelofibrosis trial and multiple 2026 clinical catalysts
$8m placement and share purchase plan
Syntara raises A$10 million to advance clinical trials and pipeline after positive FDA feedback
Continuation of trading halt
Syntara Limited extends trading halt pending capital raising announcement after positive FDA review
Positive FDA feedback for Amsulostat P2b trial
Syntara secures positive FDA feedback for Phase 2b trial of amsulostat in myelofibrosis
Trading Halt